Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,416.00
Bid: 12,408.00
Ask: 12,410.00
Change: -12.00 (-0.10%)
Spread: 2.00 (0.016%)
Open: 12,474.00
High: 12,480.00
Low: 12,350.00
Prev. Close: 12,428.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks dip on surging virus cases, stimulus doubts

Mon, 26th Oct 2020 13:22

* Unease over record virus cases in Europe, U.S.

* German DAX hits three-month low as SAP slumps

* Investors seek dollar safety

* Italy bond yields slide after S&P move

* Eyes this week on central bank meetings, U.S. GDP data

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn

By Tom Arnold and Wayne Cole

LONDON/SYDNEY, Oct 26 (Reuters) - Global shares fell on
Monday as surging coronavirus cases in Europe and the United
States clouded the global economic outlook, while China's
leaders meet to plan the country's economic future.

The United States has seen its highest-ever number of new
COVID-19 cases in the past two days. France also set case
records and Spain announced a state of emergency.

The coronavirus resurgence, along with no clear progress on
a U.S. stimulus package and caution before the Nov. 3 U.S.
election, dragged the MSCI world equity index
down 0.3%. In Europe, the Euro STOXX 600 shed 1%. S&P
500 futures fell 1%.

"The decreasing likelihood of U.S. fiscal stimulus
pre-election, possibly even pre-year-end, as well as worsening
virus numbers and increasing lockdown measures, all seem to be
taking the shine off what was a rather complacent market view of
the outlook," said James Athey, investment director at Aberdeen
Standard Investments.

Europe became the second region after Latin America to
surpass 250,000 deaths on Saturday, according to a Reuters
tally, as many European countries reported their highest number
of COVID-19 cases in a single day.

Milan's blue-chip index sank 1% as new curbs on
public venues overshadowed Friday's news that ratings agency S&P
Global had upgraded the nation's sovereign outlook to stable
from negative.

The German DAX slumped 2.7% to a three-month low
after software company SAP abandoned medium-term
profitability targets and warned its business would take longer
than expected to recover from the pandemic.

Sentiment was also hit by a survey showing German business
morale fell for the first time in six months in October.

Reports of progress in a COVID-19 vaccine being developed by
the University of Oxford and manufactured by drug maker
AstraZeneca Plc helped limit some of the market
sell-off, analysts said.

MSCI's broadest index of Asia-Pacific shares outside Japan
shed 0.2%. Japan's Nikkei finished 1%
lower, and South Korea's main index lost 0.7%.

Chinese blue chips shed 0.6% as the country's
leaders met to chart the nation's economic course for 2021-2025,
balancing growth with reforms amid an uncertain global outlook
and worsening relations with the United States.

In a packed week for monetary policy decisions, Canada's and
Japan's central banks are expected to hold fire for now. Markets
assume the European Central Bank will sound cautious on
inflation and growth even if it skips a further easing.

Data due out Thursday is forecast to show a consumer-led
31.9% rebound in U.S. economic output in the third quarter,
after the second quarter's historic collapse.

Analysts at Westpac noted such a bounce would still leave
2020 GDP around 4% below last year's, with business investment
still lagging badly.

As markets increasingly price in the likelihood of a
Democratic president and Congress and resulting rise in
government spending and borrowing, U.S. 10-year Treasury yields
hit their highest since early June last week at 0.8720%
. They were trading at 0.81% on Monday.

"We have raised the probability of a Democratic sweep,
already our base case, from 40% to just over 50% and have
increased our expectation of Biden to win from 65% to 75%,"
NatWest Markets analysts said. "We see steeper U.S. yield curves
and a weaker USD as likely to prevail in our base case."

Italian government bond yields slid across the curve, with
short-dated yields falling to a one-year low, after S&P Global's
unexpected outlook upgrade.

The benchmark 10-year yield dropped 6 basis points to 0.70%
. Short-dated two-year Italian yields hit
their lowest level in a year at -0.382%.

Surging coronavirus cases sent investors to the safety of
the dollar after it fell broadly last week.

An index tracking its value against a basket of currencies
firmed 0.1% to 92.92, while euro/dollar - the most traded
currency pair and part of the index - fell 0.3% to 1.1826
.

In commodity markets, gold was 0.1% higher at
$1,902.06 per ounce.

Oil prices extended last week's losses as the prospect of
increased supply and resurgent coronavirus infections worried
investors.

Brent crude was down 1.9% at $40.97 a barrel. U.S.
West Texas Intermediate (WTI) dropped 2.1% to $39.03.

(Reporting by Tom Arnold in London and Wayne Cole in Sydney;
editing by Shri Navaratnam, Tomasz Janowski, Larry King)

More News
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.